Back to Medicines

Dulaglutide: A Weekly GLP-1 Injection

Dulaglutide: A Weekly GLP-1 Injection
Prescription Medicines Editorial 19 October 2025

Dulaglutide is a GLP-1 receptor agonist, mimicking a gut hormone released after eating. It prompts insulin release when glucose is high, suppresses glucagon, slows stomach emptying and acts on appetite signalling. It is injected once weekly for type 2 diabetes. Its distinguishing practical feature is the device: the needle is pre-attached, hidden, and inserted automatically - you never see or handle it, which matters more to a lot of people than it sounds.

Follow the instructions on your label. This guide contains no doses.

The device

Dulaglutide comes in a single-use pen with the needle already attached and concealed. You press it against the skin, press a button, and it inserts, injects and retracts.

For anyone with needle phobia, or with dexterity or vision problems that make attaching a needle difficult, that removes the main obstacle to injectable treatment.

It is used straight from the fridge or after warming - check your product. Rotate between the abdomen, thigh and upper arm.

Used pens go in a sharps bin, not the household bin - see needles and sharps disposal.

Once weekly

Choose a day and keep to it. If you miss a dose, take it as soon as you remember provided there are at least three days before the next scheduled one; otherwise skip it.

The day can be changed if needed, as long as the gap between doses is at least three days.

Weekly dosing is a genuine advantage over daily injections - see liraglutide.

Build up slowly

Nausea, vomiting and diarrhoea are very common, worst after each dose increase, and usually settling over a few weeks.

The dose is increased in steps for that reason, and rushing it is the main reason people abandon treatment.

Practical measures: smaller portions, stopping when full, avoiding fatty and very sweet food, and not lying down straight after eating. The drug slows stomach emptying, so large meals sit uncomfortably.

If nausea is intolerable at a step, staying at the current dose longer is the standard answer rather than stopping.

What it achieves

Dulaglutide lowers HbA1c substantially and produces weight loss alongside - unusual among diabetes treatments, many of which cause weight gain.

Its cardiovascular outcome trial found a reduction in cardiovascular events in people with type 2 diabetes, including many without established cardiovascular disease - a broader population than most such trials.

Semaglutide generally produces greater weight loss and HbA1c reduction, and tirzepatide more again - see semaglutide and tirzepatide.

As with the whole class, weight returns after stopping unless something else changes. The honest framing is long-term treatment rather than a course.

What to report

Seek medical advice for severe, persistent abdominal pain radiating to the back, with or without vomiting - pancreatitis needs assessing and the drug stopping.

Report pain in the upper right abdomen after fatty meals, or jaundice - gallstones are more common with rapid weight loss and with this class.

Constipation, reflux, belching and injection site reactions are common.

Hypoglycaemia

Dulaglutide does not cause hypoglycaemia on its own, since it only enhances insulin release when glucose is raised.

Combined with insulin or a sulfonylurea it can, and those doses are often reduced when it is started - see glimepiride.

Who should not take it

People with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Anyone with a history of pancreatitis needs careful consideration.

It is not used in pregnancy and should be stopped well before conception.

Tell your anaesthetist before any procedure involving sedation, since delayed stomach emptying affects fasting requirements - guidance now addresses this specifically after cases of aspiration.

Muscle as well as fat

Substantial weight loss from any cause includes muscle. Adequate protein intake and resistance exercise matter more than usual during treatment, particularly in older people.

See medicines and your weight.

The device has a drawback too

Because the needle is hidden, you cannot see the injection going in - which reassures most people and unsettles a few, who prefer to know it has worked.

The pen clicks at the start and again at the end, and there is a viewing window that changes. Hold it against the skin until the second click and the window has changed, and do not lift it early. Injecting too soon after taking it from the fridge makes it sting more, so letting it warm for half an hour helps.

Where it fits

GLP-1 agonists are usually added when metformin and other oral treatments have not achieved control, particularly where weight or cardiovascular risk is a concern.

Access is within defined NHS criteria based on HbA1c, BMI and cardiovascular risk - see metformin and empagliflozin.

Demand has outstripped supply across this class, and falsified pens have been seized in the UK. Buy only through a registered pharmacy with a genuine prescription - see weight loss injections bought online.

Related reading: Insulin Lispro: Pumps and Faster Formulations, with more on how the main families of medicine work in Medicines.